[Corifollitropin alfa in women stimulated for the first time in in vitro fertilization programme]

OBJECTIVES

To compare results after stimulation with corifollitropin alfa (Elonva) in unselected group of women entering for the first time in in vitro fertilization programme (IVF) with results from Phase III randomized trials with selected groups of women.

DESIGN

Prospective study.

SETTING

Sanatorium Pronatal, Praha.

METHODS

40 unselected women with adequat ovarian reserve entering for the first time in IVF programme were stimulated with corifollitropin alfa and GnRH antagonists. Avarage age in the study group was 32,8 years (29-42 years), women younger then 36 and less then 60 kg received Elonva 100 µg , all others (age > 36 let, weight > 60 kg) Elonva 150 µg. Five days after egg retrieval one blastocyst was transferred (single embryo transfer - eSET). Our results were compared with the resuls in higly selected groups of women from Phase III randomized trials.

RESULTS

After stimulation with corifollitropin alfa and GnRH antagonists on average 10,6 (9,2 ± 4,2) eggs could be retrieved, among them 7,3 (6,6 ± 3,9) were M II oocytes (68,9%) and fertilisation rate was 84,6%. After first embryo transfer ("fresh" embryos and embryos from "freeze all" cycles) 14 pregnancies were achieved (37,8%), three pregnancies were achieved later from transfer of frozen-thawed embryos (cumulative pregnancy rate 45,9%). There were three abortions. No severe hyperstimulation syndrom occured. Our results in unselected group of women stimulated for the first in an IVF programme with corifollitropin alfa are fully comparable with results published in randomized trials with selected group of patiens.

CONCLUSION

Corifollitropin alfa in combination with daily GnRH antagonist can be successfully used in normal-responder patients stimulated for the first time in an IVF programmeKeywords: corifollitropin alfa, GnRH antagonists, ovarian stimulation, pregnancy.

[Successful ovarian tissue transplantation in woman with premature ovarian failure after gonadotoxic treatment]

OBJECTIVE

To demonstrate successful restoration of ovarian function after ovarian transplantation in young woman with premature ovarian failure after gonadotoxic treatment of breast carcinoma and to discuss its possibilities.

DESIGN

Case report.

SETTING

Sanatorium Pronatal, Prague.

CASE REPORT

We demonstrate successful ovarian transplantation and restoration of ovarian function in 33 years old woman after cryopreservation of ovarian tissue performed before chemotherapy and radiotherapy of breast carcinoma and discuss possibilities of this approach in women diagnosed with cancer and subsequent risk of ovarian silure.

CONCLUSION

Cryopreservation of ovarian tissue is one of efficient options to preserve fertility in young patients facing gonadotoxic treatment.

Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: conflicting results in vitro and in vivo

BACKGROUND

In this study, some important biological characteristics of two radiolabelled somatostatin analogues 111In-DOTA-1-Nal3-octreotide (DOTA-NOC) and 111In-DOTA-Tyr3-octreotate (DOTA-TATE) were compared.

MATERIALS AND METHODS

Rats were used for in vivo biodistribution experiments and in vitro cell models (OK and AR42J cell lines) were used for simulating the internalization in the kidney and in subtype 2 somatostatin receptor (SSTR2)-positive tissues, respectively.

RESULTS

Significantly higher radioactivity concentrations in rat organs with high density of somatostatin receptors after 111In-DOTA-NOC administration in comparison with 111In-DOTA-TATE were observed. The predominant urine excretion was associated with accumulation of the radioactivity in the kidney, where higher retention of 111In-DOTA-TATE compared to 111In-DOTA-NOC was detected. In the OK cell line the opposite results were found. No significant differences in the in vitro internalization and externalization of radioactivity to AR42J cell line were found for either peptide suggesting their same affinity for SSTR2.

CONCLUSION

Preclinical experiments indicated that 111In-DOTA-NOC is a very promising peptide for somatostatin receptor-positive tumour visualization. The conflict between the in vitro and in vivo kidney handling showed that the transfer of results from in vitro to in vivo conditions and their interpretation should be performed very carefully because both types of experiments can be affected by different factors, making their simple comparison difficult.

[Pharmacokinetics of salicylate in rabbits with acute renal damage]

Changes in the pharmacokinetics and metabolism of sodium salicylate were studied in rabbits with acute renal damage induced by intravenous administration of uranyl nitrate in the dose of 0.2 mg/kg. In the pathological group there occurs a marked decrease in elimination characteristics, the total plasma clearance of salicylate linearly decreasing with a decrease in the value of glomerular filtration rate. The plasma levels of creatinine and urea are suitable indices for the estimation of the changes in the plasma binding of salicylate. An increase in the fraction of free salicylate in the plasma of rabbits with acute impairment of the kidney results in a not very conclusive increase in the size of distributional volumes. In the control group mainly the unchanged drug is excreted into urine, whereas in rabbits with acute renal damage salicylate metabolites represent the majority of the eliminated amount.